Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

NCT07757568 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT07757568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07757568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)
Lead sponsor
University of Colorado, Denver
Phase
Observational
Overall status
Active, not recruiting
Start date
March 7, 2023
Completion date
November 7, 2026
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis (ms) relapsing remitting